Hospital
Bon Secours Mercy Health Petersburg LLC
Bon Secours Mercy Health Petersburg LLC was paid $48.78M by Medicaid between Jan 2020 and Dec 2024, across 322 billing codes. Its largest line is 99283, emergency room visit (moderate) — 27% of everything it billed.
33Billing provider infoBON SECOURS MERCY HEALTH PETERSBURG LLC
PETERSBURG, VA 23805
PETERSBURG, VA 23805
33aNPI1720623853assigned 11/13/2019
33bProvider typeGeneral Acute Care Hospital
28Total paid$48.78M
24GClaims1,219,036
24DCodes billed322
24AFirst – last monthJan 2020 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#16 of 80
Median peer was paid$14.69M
This provider vs. median3.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RALSTON, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 176,265 | $6.74M | |
| 2021 | 237,427 | $7.57M | |
| 2022 | 255,838 | $9.62M | |
| 2023 | 298,255 | $12.54M | |
| 2024incomplete | 251,251 | $12.31M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 77,789 | 67,007 | $12.98M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 46,063 | 38,756 | $7.41M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.1% | 26,971 | 22,566 | $4.41M |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.0% | 10,123 | 8,174 | $2.93M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.9% | 15,488 | 13,335 | $2.41M |
| 70450 | Computed tomography, head or brain; without contrast material | 3.9% | 10,704 | 9,248 | $1.91M |
| G0378 | Hospital observation service, per hour | 2.6% | 8,676 | 4,839 | $1.26M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.5% | 6,820 | 5,939 | $1.24M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.9% | 19,128 | 4,784 | $934K |
| 93458 | 1.7% | 663 | 571 | $826K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.6% | 4,787 | 4,157 | $805K |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 2,406 | 2,109 | $557K |
310 more codes
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.1% | 8,892 | $518K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.0% | 1,017 | $488K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,233 | $433K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,092 | $425K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,462 | $423K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 7,829 | $403K |
| 36415 | Collection of venous blood by venipuncture | <1% | 63,247 | $386K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 3,005 | $363K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 4,227 | $323K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,851 | $318K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 2,378 | $275K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 479 | $256K |
| 97161 | <1% | 2,490 | $254K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 28,335 | $252K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,417 | $194K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,538 | $178K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 312 | $178K |
| 76830 | Ultrasound, transvaginal | <1% | 1,911 | $175K |
| 80053 | Comprehensive metabolic panel | <1% | 49,207 | $165K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,262 | $165K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 735 | $163K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,003 | $158K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 5,797 | $156K |
| 70496 | <1% | 772 | $149K | |
| 93971 | <1% | 1,647 | $145K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,086 | $131K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,697 | $131K |
| 76642 | <1% | 1,254 | $128K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 20,036 | $125K |
| 12001 | <1% | 687 | $120K | |
| 11045 | <1% | 294 | $117K | |
| 93970 | <1% | 896 | $104K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 4,409 | $100K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 3,425 | $99K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,477 | $91K |
| 97162 | <1% | 710 | $80K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 452 | $77K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 16,845 | $73K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 418 | $70K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 556 | $68K |
| 36430 | <1% | 599 | $68K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 175 | $64K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 24,816 | $64K |
| 83880 | <1% | 7,075 | $62K | |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 67 | $61K |
| 71045 | Radiologic examination, chest; single view | <1% | 24,320 | $58K |
| 81001 | <1% | 38,149 | $57K | |
| 97014 | <1% | 2,211 | $56K | |
| 71250 | <1% | 1,169 | $54K | |
| 76536 | <1% | 507 | $52K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 34,847 | $51K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 3,345 | $50K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 3,810 | $50K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 7,616 | $47K |
| 72131 | <1% | 648 | $47K | |
| 70486 | <1% | 1,220 | $41K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,326 | $40K |
| 76801 | <1% | 1,343 | $40K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 2,010 | $40K |
| 70498 | <1% | 950 | $38K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 404 | $35K |
| 73630 | <1% | 2,895 | $34K | |
| 77336 | <1% | 258 | $34K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 3,957 | $34K |
| 12011 | <1% | 203 | $34K | |
| 10060 | <1% | 548 | $34K | |
| 73562 | <1% | 2,811 | $34K | |
| 86901 | <1% | 6,328 | $34K | |
| 73610 | <1% | 2,734 | $33K | |
| 74018 | <1% | 3,322 | $33K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 17,693 | $32K |
| 82962 | <1% | 21,315 | $32K | |
| 73030 | <1% | 2,861 | $32K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 310 | $32K |
| 97165 | <1% | 882 | $32K | |
| 76770 | <1% | 298 | $31K | |
| C1769 | Guide wire | <1% | 2,364 | $29K |
| 59025 | Fetal non-stress test | <1% | 190 | $28K |
| 73130 | <1% | 2,513 | $28K | |
| 85730 | <1% | 3,930 | $27K | |
| 74178 | <1% | 117 | $26K | |
| 84484 | <1% | 28,439 | $26K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 679 | $26K |
| 87807 | <1% | 2,528 | $25K | |
| 87040 | <1% | 4,658 | $25K | |
| 81025 | <1% | 15,317 | $25K | |
| 72100 | <1% | 1,884 | $25K | |
| 90714 | <1% | 1,259 | $24K | |
| 93798 | <1% | 171 | $23K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,228 | $23K |
| 71271 | <1% | 206 | $23K | |
| 77066 | Tomosynthesis, mammo | <1% | 496 | $22K |
| 77065 | Tomosynthesis, mammo | <1% | 524 | $22K |
| 0042T | <1% | 168 | $22K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 99 | $21K |
| 70491 | <1% | 85 | $21K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 60,424 | $20K |
| 87641 | <1% | 1,187 | $19K | |
| 73502 | <1% | 1,786 | $18K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,611 | $18K |
| 12002 | <1% | 116 | $17K | |
| 90715 | <1% | 1,073 | $17K | |
| 97116 | <1% | 784 | $16K | |
| 73110 | <1% | 1,476 | $15K | |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,738 | $13K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 15 | $13K |
| 82565 | <1% | 1,120 | $13K | |
| 11043 | <1% | 131 | $12K | |
| 97163 | <1% | 177 | $12K | |
| 92610 | <1% | 188 | $11K | |
| 85027 | <1% | 6,944 | $11K | |
| 85379 | <1% | 2,688 | $10K | |
| 90935 | Hemodialysis procedure with single evaluation by a physician | <1% | 18 | $10K |
| 86850 | <1% | 5,339 | $9K | |
| 93880 | <1% | 90 | $9K | |
| 84702 | <1% | 3,630 | $9K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 50 | $9K |
| 76937 | <1% | 393 | $9K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 19,285 | $9K |
| 73140 | <1% | 677 | $8K | |
| 93308 | <1% | 20 | $8K | |
| 86900 | <1% | 6,329 | $8K | |
| 84132 | <1% | 2,127 | $8K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 16,820 | $8K |
| 73564 | <1% | 877 | $8K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 437 | $8K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,775 | $7K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 7,954 | $7K |
| 87077 | <1% | 2,741 | $7K | |
| 73080 | <1% | 719 | $7K | |
| 80179 | <1% | 1,379 | $6K | |
| 73590 | <1% | 907 | $6K | |
| 80050 | General health panel | <1% | 644 | $6K |
| 76870 | <1% | 94 | $6K | |
| 86923 | <1% | 423 | $6K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,320 | $5K |
| 84145 | <1% | 1,421 | $5K | |
| 80143 | <1% | 1,374 | $5K | |
| 73552 | <1% | 150 | $5K | |
| 80047 | <1% | 889 | $5K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 18,330 | $4K |
| 72141 | <1% | 28 | $4K | |
| 95816 | <1% | 20 | $4K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,386 | $4K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 8,739 | $4K |
| 87070 | <1% | 6,310 | $4K | |
| 99218 | <1% | 171 | $4K | |
| 96376 | <1% | 7,721 | $4K | |
| 71101 | <1% | 201 | $4K | |
| 77290 | <1% | 31 | $4K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 8,623 | $4K |
| J2704 | Injection, propofol, 10 mg | <1% | 9,209 | $4K |
| 72050 | <1% | 272 | $3K | |
| 72110 | <1% | 173 | $3K | |
| 87210 | <1% | 3,115 | $3K | |
| 87088 | <1% | 287 | $3K | |
| 87205 | <1% | 1,301 | $3K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,665 | $3K |
| 74174 | <1% | 27 | $3K | |
| 85610 | <1% | 6,310 | $3K | |
| C1887 | Catheter, guiding (may include infusion/perfusion capability) | <1% | 230 | $3K |
| 97010 | <1% | 174 | $3K | |
| 88307 | <1% | 128 | $3K | |
| 83690 | <1% | 12,513 | $3K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 567 | $3K |
| 73090 | <1% | 415 | $2K | |
| 80061 | Lipid panel | <1% | 1,155 | $2K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,772 | $2K |
| 73560 | <1% | 129 | $2K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 51 | $2K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 3,082 | $2K |
| 82077 | <1% | 5,025 | $2K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 82 | $2K |
| 97166 | <1% | 13 | $2K | |
| 77080 | <1% | 28 | $2K | |
| 81003 | <1% | 3,514 | $2K | |
| 83605 | <1% | 6,568 | $2K | |
| 84703 | <1% | 5,203 | $2K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,972 | $2K |
| 87147 | <1% | 1,752 | $2K | |
| 83735 | <1% | 8,183 | $1K | |
| 86140 | <1% | 1,272 | $1K | |
| 80076 | <1% | 1,490 | $1K | |
| 77062 | <1% | 208 | $1K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,816 | $1K |
| 80069 | <1% | 554 | $1K | |
| 93325 | <1% | 32 | $1K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 8,265 | $1K |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 909 | $1K |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,272 | $948.37 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,793 | $893.18 |
| 87808 | <1% | 2,186 | $834.57 | |
| 83615 | <1% | 107 | $736.49 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 262 | $728.12 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,107 | $710.91 |
| 88341 | <1% | 15 | $708.69 | |
| 73660 | <1% | 33 | $660.67 | |
| 82550 | <1% | 2,593 | $635.38 | |
| J2404 | Injection, nicardipine, 0.1 mg | <1% | 13 | $556.30 |
| 87186 | <1% | 2,868 | $530.06 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 13,842 | $527.90 |
| 72040 | <1% | 53 | $519.10 | |
| 87634 | <1% | 277 | $517.27 | |
| 88342 | <1% | 239 | $488.82 | |
| 76000 | <1% | 235 | $479.87 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 1,028 | $454.51 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 6,269 | $421.95 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,787 | $419.65 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 90 | $412.70 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,365 | $412.27 |
| 94760 | <1% | 829 | $411.56 | |
| 73060 | <1% | 45 | $394.91 | |
| 82272 | <1% | 145 | $372.45 | |
| 82247 | <1% | 94 | $371.30 | |
| 72072 | <1% | 48 | $369.93 | |
| 72170 | <1% | 275 | $360.95 | |
| 77061 | <1% | 75 | $350.78 | |
| 99152 | <1% | 1,642 | $321.46 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,087 | $314.73 |
| 82803 | <1% | 1,207 | $278.19 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 4,113 | $259.85 |
| 70360 | <1% | 13 | $257.00 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 5,525 | $240.94 |
| 73620 | <1% | 26 | $226.69 | |
| 93017 | <1% | 32 | $224.71 | |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 1,529 | $220.19 |
| 84520 | <1% | 46 | $219.49 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 33 | $192.75 |
| 85652 | <1% | 728 | $190.48 | |
| 88304 | <1% | 665 | $167.38 | |
| 80177 | <1% | 125 | $159.05 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 977 | $150.08 |
| 85018 | <1% | 485 | $148.93 | |
| 84439 | <1% | 86 | $133.50 | |
| 82553 | <1% | 114 | $128.12 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 660 | $122.59 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 1,171 | $117.14 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 644 | $105.45 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,706 | $104.45 |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 1,194 | $100.23 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,049 | $84.15 |
| 82607 | <1% | 58 | $76.80 | |
| 80164 | <1% | 19 | $76.23 | |
| 85014 | <1% | 130 | $65.48 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 589 | $62.63 |
| 82140 | <1% | 90 | $60.76 | |
| 82570 | <1% | 139 | $60.11 | |
| 94762 | <1% | 298 | $58.41 | |
| 82248 | <1% | 572 | $55.82 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 1,063 | $52.59 |
| 82746 | <1% | 32 | $52.20 | |
| 83540 | <1% | 81 | $51.15 | |
| 84550 | <1% | 159 | $51.13 | |
| 82805 | <1% | 64 | $46.64 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,031 | $42.65 |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 1,106 | $41.44 |
| 84100 | <1% | 434 | $37.18 | |
| J1815 | Injection, insulin, per 5 units | <1% | 326 | $34.40 |
| J3490 | Unclassified drugs | <1% | 7,085 | $26.15 |
| 82150 | <1% | 57 | $23.88 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 616 | $15.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 606 | $13.46 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 2,774 | $12.33 |
| 82728 | <1% | 32 | $12.23 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 15 | $9.06 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 134 | $8.74 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 69 | $7.45 |
| 94761 | <1% | 2,808 | $6.39 | |
| 84156 | <1% | 29 | $5.39 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 67 | $3.38 |
| 82947 | <1% | 554 | $3.16 | |
| J8597 | Antiemetic drug, oral, not otherwise specified | <1% | 37 | $1.65 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 32 | $1.61 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 271 | $1.28 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 32 | $0.80 |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 16 | $0.54 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 602 | $0.00 |
| 84295 | 0% | 520 | $0.00 | |
| 29125 | 0% | 84 | $0.00 | |
| 96367 | 0% | 126 | $0.00 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 0% | 69 | $0.00 |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 91 | $0.00 |
| T5999 | Supply, not otherwise specified | 0% | 77 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 262 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 449 | $0.00 |
| 87150 | 0% | 14 | $0.00 | |
| 93356 | 0% | 52 | $0.00 | |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 138 | $0.00 |
| J3486 | Injection, ziprasidone mesylate, 10 mg | 0% | 18 | $0.00 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 27 | $0.00 |
| 88312 | 0% | 27 | $0.00 | |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 391 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 111 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 38 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 84 | $0.00 |
| 82330 | 0% | 567 | $0.00 | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | 0% | 13 | $0.00 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 1,274 | $0.00 |
| 77417 | 0% | 30 | $0.00 | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 0% | 66 | $0.00 |
| 86592 | 0% | 30 | $0.00 | |
| J0456 | Injection, azithromycin, 500 mg | 0% | 26 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 69 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 13 | $0.00 |
| C9399 | Unclassified drugs or biologicals | 0% | 23 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 166 | $0.00 |
| 96368 | 0% | 14 | $0.00 | |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 73 | $0.00 |
| A9609 | Fludeoxyglucose f18 up to 15 millicuries | 0% | 13 | $0.00 |
| 87340 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRALSTON, KIMBERLY (SYSTEM DIRECTOR)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.